摘要
目的介绍有机阴离子转运多肽1B1(OATP1B1)的研究进展。方法查阅国外有关文献,并对其进行分析、归纳和总结。结果OATP1B1存在遗传多态性,且不同等位基因所表达的OATP1B1的转运能力具有显著性差异,进而会对多种药物的药动学及药效学产生影响;OATP1B1还与药物不良反应及药物相互作用有关。结论基于OATP1B1对药物体内过程的重要作用,关注OATP1B1遗传多态性对药动学、药效学的影响,及其与不良反应及药物相互作用的关系具有一定临床意义。
关键词
OATP1B1 /
药动学 /
药效学 /
不良反应 /
相互作用
{{custom_keyword}} /
温爱萍;徐小薇.
有机阴离子转运多肽1B1的研究进展[J]. 中国药学杂志, 2008, 43(23): 1765-1769
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] TIRONA R G,LEAKE B F,MERINO G,et al. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European-and African-Americans[J] . J Biol Chem,2001,276 (38): 35669-35675.
[2] NOZAWA T,NAKAJIMA M,TAMAI I,et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allelic frequencies in the Japanese population and functional analysis[J] . J Pharmacol Exp Ther,2002,302 (2): 804-813.
[3] HSIANG B,ZHU Y,WANG Z,et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters[J] . J Biol Chem,1999,274(52): 37161-37168.
[4] KNIG J,CUI Y,NIES A T,et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane[J] . Am J Physiol,2000,278 (1):156-164.
[5] CUI Y,KONIG J,LEIER I,et al. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6[J] . J Biol Chem,2001,276(13): 9626-9630.
[6] NAKAI D,NAKAGOMI R,FURUTA Y,et al. Human liver-specific organic anion transporter,LST-1,mediates uptake of pravastatin by human hepatocytes[J] . J Pharmacol Exp Ther,2001,297 (3): 861-867.
[7] LENNERNAS H. Clinical pharmacokinetics of atorvastatin[J] . Clin Pharmacokinet,2003,42(13): 1141-1160.
[8] HIRANO M,MAEDA K,SHITARA Y,et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans[J] . J Pharmacol Exp Ther,2004,311(1): 139-146.
[9] HO R H,TIRONA R G,LEAKE B F,et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function,expression,and pharmacogenetics[J] . Gastroenterology,2006,130(6): 1793-1806.
[10] PASANEN M K,NEUVONEN M,NEUVONEN P J,et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid[J] . Pharmacogenet Genomics,2006,16(12): 873-879.
[11] ABE T,UNNO M,ONOGAWA T,et al. LST-2,a human liver-specific organic anion transporter,determines methotrexate sensitivity in gastrointestinal cancers[J] . Gastroenterology,2001,120 (7): 1689-1699.
[12] NOZAWA T,MINAMI H,SUGIURA S,et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite,7-ethyl -10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms[J] . Drug Metab Dispos,2005,33(3): 434-439.
[13] SANDHU P,LEE W,XU X,et al. Hepatic uptake of the novel antifungal agent caspofungin[J] . Drug Metab Dispos,2005,33(5): 676-682.
[14] YAMASHIRO W,MAEDA K,HIROUCHI M,et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan,a selective antagonist of the angiotensin II AT1-receptor,in humans[J] . Drug Metab Dispos,2006,34(7): 1247-1254.
[15] NAKAGOMI-HAGIHARA R,NAKAI D,KAWAI K,et al. OATP 1B1,OATP1B3,and mrp2 are involved in hepatobiliary transport of olmesartan,a novel angiotensin II blocker[J] . Drug Metab Dispos,2006,34(5): 862-869.
[16] NIEMI M,SCHAEFFELER E,LANG T,et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C,SLCO1B1)[J] . Pharmacogenetics,2004,14(7): 429-440.
[17] PASANEN M K,BACKMAN J T,NEUVONEN P J,et al. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population[J] . Eur J Clin Pharmacol,2006,62 (6): 409-415.
[18] NISHIZATO Y,IEIRI I,SUZUKI H,et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics[J] . Clin Pharmacol Ther,2003,73(6): 554-565.
[19] IWAI M,SUZUKI H,IEIRI I,et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C)[J] . Pharmacogenetics,2004,14(11): 749-757.
[20] MWINYI J,JOHNE A,BAUER S,et al. Evidence for inverse effects of OATP1B1 (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics[J] . Clin Pharmacol Ther,2004,75(5): 415-421.
[21] CHUNG J Y,CHO J Y,YU K S,et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers[J] . Clin Pharmacol Ther,2005,78(4): 342-350.
[22] NIEMI M,BACKMAN J T,KAJOSAARI L I,et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics[J] . Clin Pharmacol Ther,2005,77(6): 468-478.
[23] ZHANG W,HE Y J,HAN C T,et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide[J] . Br J Clin Pharmacol,2006,62(5): 567-572.
[24] XIANG X,JADA S R,LI H H,et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients[J] . Pharmacogenet Genomics,2006,16(9): 683-691.
[25] KIM R B. 3-HYDROXY-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?[J] . Clin Pharmacol Ther,2004,75(5): 381-385.
[26] NIEMI M,NEUVONEN P J,HOFMANN U,et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17[J] . Pharmacogenet Genomics,2005,15(5): 303-309.
[27] IGEL M,ARNOLD K A,NIEMI M,et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin[J] . Clin Pharmacol Ther,2006,79(5): 419-426.
[28] CAMPBELL S D,DE MORAIS S M,XU J J. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia[J] . Chem Biol Interact,2004,150(2): 179-187.
[29] HAMILTON-CRAIG I. Statin-associated myopathy[J] . Med J Aust,2001,175(9): 486-489.
[30] MORIMOTO K,OISHI T,UEDA S,et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy[J] . Drug Metab Pharmacokinet,2004,19(6): 453-455.
[31] SHITARA Y,ITOH T,SATO H,et al. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A[J] . J Pharmacol Exp Ther,2003,304(2): 610-616.
[32] SHITARA Y,HIRANO M,ADACHI Y,et al. In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats[J] . Drug Metab Dispos,2004,32(12): 1468-1475.
[33] YAMAZAKI M,LI B,LOUIE S W,et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-,multidrug resistance protein 2- and P-glycoprotein-mediated transport[J] . Xenobiotica,2005,35(7): 737-753.
[34] VAVRICKA S R,VAN MONTFOORT J,HA H R,et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver[J] . Hepatology,2002,36(1): 164-172.
[35] ISMAIR M G,STANCA C,HA H R,et al. Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver[J] . Hepatol Res,2003,26(4): 343-347.
[36] WANG X,WOLKOFF A W,MORRIS M E. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators[J] . Drug Metab Dispos,2005,33(11): 1666-1672.
[37] SEITHEL A,EBERL S,SINGER K,et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3[J] . Drug Metab Dispos,2007,35(5): 779-786.
[38] ENDRES C J,HSIAO P,CHUNG F S,et al. The role of transporters in drug interactions[J] . Eur J Pharm Sci,2006,27(5): 501-517.
[39] SIMONSON S G,RAZA A,MARTIN P D,et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine[J] . Clin Pharmacol Ther,2004,76(2): 167-177.
[40] HIRATA-KOIZUMI M,SAITO M,MIYAKE S,et al. Incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan[J] . Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku,2005(123): 37-40.
[41] SHITARA Y,HIRANO M,SATO H,et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil[J] . J Pharmacol Exp Ther,2004,311(1): 228-236.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}